Trinity College Dublin

Skip to main content.

Top Level TCD Links

Andrew Harkin
Associate Professor in Pharmacology, Pharmacy
Deputy Director of TCIN, Trinity Inst. of Neurosciences (TCIN)

Biography

Andrew Harkin is Associate Professor of Pharmacology in The School of Pharmacy & Pharmaceutical Sciences in Trinity College Dublin and a principle investigator in Trinity College Institute of Neuroscience. He leads a neuropsychopharmacology research group which is focused on bridging neuroscience to the pharmacological treatment of psychiatric and neurological disorders. Current research interests include- - bidirectional nervous system immune interactions, the role of inflammation in the pathogenesis, and potential of anti-inflammatory agents in treating, psychiatric disorders. - targeting the N-methyl-D-aspartic acid (NMDA) receptor and the NMDA-nitric oxide-cGMP intra-neuronal signalling in stress related psychiatric disorders. Professor Harkin's research program is funded by the European Commission (Framework 7), Science Foundation Ireland, the Irish Health Research Board and the Irish Research Council for Science Engineering and Technology, His group collaborates widely with a variety of academic and industrial partners on fundamental and clinical projects.

Publications and Further Research Outputs

Peer-Reviewed Publications

Abautret-Daly Á, Dempsey E, Riestra S, de Francisco-García R, Parra-Blanco A, Rodrigo L, Medina C, Connor TJ, Harkin A., Association between psychological measures with inflammatory and disease-related markers of inflammatory bowel disease, International Journal of Psychiatry & Clinical Practise, Mar 29, 2017, p1 - 10 Journal Article, 2017 DOI

O'Farrell K, Fagan E, Connor T.J, Harkin A, Inhibition of the kynurenine pathway protects against reactive microglial-associated reductions in the complexity of primary cortical neurons, European Journal of Pharmacology, 810, 2017, p163 - 173 Journal Article, 2017 DOI URL

Sherwin E, Gigliucci V, Harkin A, Regional specific modulation of neuronal activation associated with nitric oxide synthase inhibitors in an animal model of antidepressant activity, Behavioural Brain Research, 316, 2017, p18 - 28 Journal Article, 2017 DOI URL

Abautret-Daly Á, Dempsey E, Riestra S, de Francisco-García R, Parra-Blanco A, Rodrigo L, Medina C, Connor TJ, Harkin A., Gut-brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease, Acta Neuropsychiatr, March 8, 2017, p1 - 22 Review Article, 2017 DOI

McIntosh A.L, Gormley S, Tozzi L, Frodl T, Harkin A, Recent advances in translational magnetic resonance imaging in animal models of stress and depression, Frontiers in Cellular Neuroscience, 11, 2017, p00150- Journal Article, 2017 TARA - Full Text DOI URL

Maria N.I, van Helden-Meeuwsen C.G, Brkic Z, Paulissen S.M.J, Steenwijk E.C, Dalm V.A, van Daele P.L, Martin van Hagen P, Kroese F.G.M, van Roon J.A.G, Harkin A, Dik W.A, Drexhage H.A, Lubberts E, Versnel M.A, Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's Syndrome, Arthritis and Rheumatology, 68, (7), 2016, p1688 - 1699 Journal Article, 2016 URL DOI

Hughes M.M, Connor T.J, Harkin A, Stress-Related Immune Markers in Depression: Implications for Treatment, International Journal of Neuropsychopharmacology, 19, (6), 2016, p1 - 19 Journal Article, 2016 URL TARA - Full Text DOI

Novel Targets in the Glutamate and Nitric Oxide Neurotransmitter Systems for the Treatment of Depression in, editor(s) , Systems Neuroscience in Depression, 2016, pp81-113 , [O'Toole, E., Doucet, M.V., Sherwin, E., Harkin, A.] Book Chapter, 2016 DOI

McGuiness B, Gibney S.M, Beumer W, Versnel M.A, Sillaber I, Harkin A, Drexhage H.A, Exaggerated increases in microglia proliferation, brain inflammatory response and sickness behaviour upon lipopolysaccharide stimulation in non-obese diabetic mice, NeuroImmunoModulation, 23, (3), 2016, p137 - 150 Journal Article, 2016 DOI URL

O'Neill E, Kwok B, Day J.S, Connor T.J, Harkin A, Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism, Pharmacology Research and Perspectives, 4, (2), 2016 Journal Article, 2016 URL DOI

Ryan K.M, Griffin à .W, Ryan K.J, Tanveer R, Vanattou-Saifoudine N, McNamee E.N, Fallon E, Heffernan S, Harkin A, Connor T.J, Clenbuterol activates the central IL-1 system via the β2-adrenoceptor without provoking inflammatory response related behaviours in rats, Brain, Behavior, and Immunity, 56, 2016, p114 - 129 Journal Article, 2016 DOI URL

Gormley, S., Rouine, J., McIntosh, A., Kerskens, C., Harkin, A., Glial fibrillary acidic protein (GFAP) immunoreactivity correlates with cortical perfusion parameters determined by bolus tracking arterial spin labelling (bt-ASL) magnetic resonance (MR) imaging in the Wistar Kyoto rat, Physiology and Behavior, 160, 2016, p66-79 Journal Article, 2016 DOI

Rouine J, Kelly ME, Jennings-Murphy C, Duffy P, Gorman I, Gormley S, Kerskens CM, Harkin A, Investigation of the mechanisms mediating MDMA "Ecstasy"-induced increases in cerebro-cortical perfusion determined by btASL MRI., Psychopharmacology, 232, (9), 2015, p1501-1513 Journal Article, 2015 DOI

O'Farrell, K., Harkin, A., Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders, Neuropharmacology, 2015 Journal Article, 2015 TARA - Full Text DOI

Murray, C., Griffin, E.W., O'Loughlin, E., (...), Harkin, A., Cunningham, C., Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I: C, Brain, Behavior, and Immunity, 48, 2015, 274-286 Journal Article, 2015 TARA - Full Text

Rodent Models of Stress-Induced Depression: The link between stress and immune system related changes in, editor(s)Norbert Muller, Aye-Mu Myint, Markus J Schwarz , Immunology and Psychiatry; from basic research to therapeutic interventions, Switzerland, Springer, 2015, pp33 - 62, [McGuinness B, Harkin A] Book Chapter, 2015

Inflammation in the pathogenesis of depression in, editor(s)Nicola Woodroofe, Sandra Amor , Neuroinflammation and CNS Disorders, United Kingdom, Wiley Blackwell, 2015, pp261 - 288, [Thomas J. Connor and Andrew Harkin] Book Chapter, 2015

Doucet MV, O'Toole E, Connor T, Harkin A, Small molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuornal atrophy in primary cortical neurons, Neuroscience, 301, 2015, p421 - 438 Journal Article, 2015

Morgese, M.G., Colaianna, M., Mhillaj, E., Zotti, M., Schiavone, S., D'Antonio, P., Harkin, A., Gigliucci, V., Campolongo, P., Trezza, V., De Stradis, A., Tucci, P., Cuomo, V., Trabace, L., Soluble beta amyloid evokes alteration in brain norepinephrine levels: Role of nitric oxide and interleukin-1, Frontiers in Neuroscience, 9, (NOV), 2015, p2015 Journal Article, 2015 TARA - Full Text DOI

O'Donovan S*, Dalton VS*, Harkin A, McLoughlin DM; * joint first author, Effects of brief pulse and ultrabrief pulse electroconvulsive stimulation on rodent brain and behaviour in the corticosterone model of depression. , International Journal of Neuropsychopharmacology. DOI: 10.1017/S1461145714000500, 17, (9), 2014, p1477 - 1486 Journal Article, 2014 DOI

Harkin A, Muscling in on Depression, New England Journal of Medicine, 371, (24), 2014, p2333 - 2334 Journal Article, 2014

Cuartero MI, Ballesteros I, de la Parra J, Harkin A, Abautret-Daly A, Sherwin E, Fernandez-Salguero P, Corbi AL, Lizasoain I, Moro MA, L-kynurenine/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke, Circulation, 130, (23), 2014, p2040 - 2051 Journal Article, 2014

Gigliucci V, Gormley S, Gibney S, Rouine J, Kerskens C, Connor TJ, Harkin A, Characterisation of the antidepressant properties of nitric oxide synthase inhibitors in the olfactory bulcectomised rat model of depression, European Neuropsychopharmacology, 24, (8), 2014, p1349 - 1361 Journal Article, 2014 DOI

Gibney S, Fagan EM, Waldron AM, O'Byrne J, Connor TJ, Harkin A , Inhibition of stress-induced heaptic tryptophan 2,3 di-oxygenase exhibits antidepressant activity in an animal model of depressive behaviour, International Journal of Neuropsychopharmacology, 17, (6), 2014, p917 - 928 Journal Article, 2014

Frodl T, Carballedo A, Frey EM, O'Keane V, Skokauskas N, Morris D, Gill M, Hughes MM, Harkin A, Connor T, Expression of glucocorticoid inducible genes is associated with reductions in cornu ammonis and dentate gyrus volumes in patients with major depressive disorder., Development and psychopathology, 26, (4 Pt 2), 2014, p1209-17 Journal Article, 2014 DOI TARA - Full Text

Rouine J, Gobbo OL, Campbell M, Gigliucci V, Ogden I, McHugh Smith K, Duffy P, Behan B, Byrne D, Kelly ME, Blau CW, Kerskens CM, Harkin A, MDMA 'ecstasy' increases cerebral cortical perfusion determined by bolus-tracking arterial spin labelling (btASL) MRI., British journal of pharmacology, 169, (5), 2013, p974-87 Journal Article, 2013

Pertl, M.M., Hevey, D., Boyle, N.T., Hughes, M.M., Collier, S., O'Dwyer, A.M., Harkin, A., Kennedy, M.J., & Connor, T.J., C-reactive prtoein predicts fatigue independently of depression in breast cancer patients prior to chemotherapy, Brain Behaviour and Immunity, 34, 2013, p108 - 119 Journal Article, 2013 DOI

Ryan KJ, Griffin E, Yssel JD, Ryan KM, McNamee EN, Harkin A, Connor TJ, Stimulation of central ß2-adrenoceptors suppresses NFkB activity in rat brain: A role for IkB., Neurochemistry international, 63, (5), 2013, p368-378 Journal Article, 2013

Day JS, O'Neill E, Cawley C, Aretz NK, Kilroy D, Gibney SM, Harkin A, Connor TJ, Noradrenaline acting on astrocytic ß2-adrenoceptors induces neurite outgrowth in primary cortical neurons., Neuropharmacology, 77C, 2013, p234-248 Journal Article, 2013 DOI

Doucet MV, Levine H, Dev KK, Harkin A, Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice., Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, (8), 2013, p1575-1584 Journal Article, 2013 DOI

Gibney SM, McGuinness B, Prendergast C, Harkin A, Connor TJ, Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression., Brain, behavior, and immunity, 28, 2013, p170-81 Journal Article, 2013

Gigliucci V, O'Dowd G, Casey S, Egan D, Gibney S, Harkin A, Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism., Psychopharmacology, 228, (1), 2013, p157-66 Journal Article, 2013

Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, Connor TJ, Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation, Brain Behavior and Immunity, 26, 2012, p979 - 987 Journal Article, 2012

Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, Steiner J, Connor TJ, Harkin A, Versnel MA, Drexhage HA, The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes., Journal of leukocyte biology, 92, (5), 2012, p959-75 Journal Article, 2012

Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS complex: New drugs for depression?, Pharmacology and Therapeutics, 133, (2), 2012, p218-29 Journal Article, 2012 DOI

Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS Complex: New Drugs for Depression?, Pharmacology & Therapeutics, 133, 2012, p218 - 229 Journal Article, 2012 TARA - Full Text

Vanattou-Saifoudine N, McNamara R, Harkin A, Caffeine provokes adverse interactions with MDMA ("Ecstasy") and related psychostimulants: mechanisms and mediators, British Journal of Pharmacology, 2012, pEpub ahead of print Journal Article, 2012

Vanattou-Saifoudine N, Behan B, Harkin A, Dopamine D1 receptor mediated intracellular responses in the hypothalamus after co-administration of caffeine with MDMA, Basic and Clinical Pharmacology and Toxicology, 110, 2012, p283 - 289 Journal Article, 2012

Hughes MM, Carballedo A, McLoughlin DM, Amico F, Harkin A, Frodl T, Connor TJ, Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation., Brain, behavior, and immunity, 26, (6), 2012, p979-987 Journal Article, 2012 DOI

Natacha Vanattou-Saïfoudine, Anna Gossen, Andrew Harkin, A role for adenosine A1 receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release , European Journal of Pharmacology , 650, (1), 2011, p220-228 Journal Article, 2011 TARA - Full Text

Gigliucci V, Buckley KN, Nunan J, O'Shea K, Harkin A, A role for serotonin in the antidepressant activity of N(G)-Nitro-L-arginine, in the rat forced swimming test., Pharmacology, biochemistry, and behavior, 94, (4), 2010, p524-533 Journal Article, 2010 DOI

E.N. McNamee, K.M. Ryan, E.W. Griffin, R.E. González-Reyes, K.J. Ryan, A. Harkin and T.J. Connor, Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: Implications for neurodegeneration, Brain Behavior and Immunity, 24, (4), 2010, p660 - 671 Journal Article, 2010 DOI

Vanattou-Saïfoudine N, McNamara R, Harkin A, Caffeine promotes dopamine D(1) receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy')., Psychopharmacology, 211, (1), 2010, p15-25 Journal Article, 2010 DOI

J.B. O'Sullivan, K.M. Ryan, A. Harkin and T.J. Connor, Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge, Journal of Neuroimmunology, 220, (1-2), 2010, p34 - 42 Journal Article, 2010 DOI

L.C. Gleeson, K.J. Ryan, E.W. Griffin, T.J. Connor and A. Harkin, The beta2-adrenoceptor agonist clenbuterol elicits neuroprotective, anti-inflammatory and neurotrophic actions in the kainic acid model of excitotoxicity , Brain Behavior and Immunity, 24, (8), 2010, p1354 - 1361 Journal Article, 2010 DOI

O'Sullivan JB, Ryan KM, Harkin A, Connor TJ, Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge., Journal of neuroimmunology, 220, (1-2), 2010, p34-42 Journal Article, 2010 DOI

Vanattou-Saifoudine N, McNamara R, Harkin A., Mechanisms mediating the ability of caffeine to influence MDMA ("Ecstasy")-induced hyperthermia in rats. , British Journal of Pharmacology, 160, 2010, p860 - 877 Journal Article, 2010

E.N. McNamee, E.W. Griffin, K.M. Ryan, K.J. Ryan, S. Heffernan, A. Harkin and T.J. Connor, Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex, Neuropharmacology, 59, (1-2), 2010, p37 - 48 Journal Article, 2010 TARA - Full Text

J.B. O'Sullivan, K.M. Ryan, N.M. Curtin, A. Harkin and T.J. Connor, Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration., International Journal of Neuropsychopharmacology , 12, (5), 2009, p687 - 699 Journal Article, 2009 TARA - Full Text DOI

Valentina Gigliucci, Kathleen Niamh Buckley, John Nunan, Karen O'Shea and Andrew Harkin, A role for serotonin in the antidepressant activity of NG Nitro-L-arginine in the rat forced swimming test, Pharmacology Biochemistry and Behavior, 2009 Journal Article, 2009 TARA - Full Text DOI

M. Roche, E. Shanahan, A. Harkin, J.P. Kelly, Trans-species assessment of antidepressant activity in a rodent model of depression, Pharmacological Reports, 60, (3), 2008, p404 - 408 Journal Article, 2008 URL

S. Durkin, A. Prendergast, A. Harkin, Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats, Progress in Neuropsychopharmacology and Biological Psychiatry, 32, (8), 2008, p1894 - 1901 Journal Article, 2008 DOI

T.J. Connor, N. Starr, J.B. O'Sullivan and A. Harkin, Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?, Neuroscience Letters, 441, (1), 2008, p29 - 34 Journal Article, 2008 DOI

M.R. Garland, B. Hallahan, M. McNamara, P.A. Carney, H. Grimes, J.R. Hibbeln, A. Harkin, R.M. Conroy , Lipids and essential fatty acids in patients presenting with self-harm., British Journal of Psychiatry , 190, 2007, p112 - 117 Journal Article, 2007 DOI

M. Roche, A. Harkin, J.P. Kelly, Chronic fluoxetine treatment attenuates stressor-induced changes in temperature, heart rate and neuronal activation in the olfactory bulbectomised rat, Neuropsychopharmacology, 32, (6), 2007, p1312-1320 Journal Article, 2007 DOI

R. McNamara, M. Maginn, A. Harkin, Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration, European Journal of Pharmacology, 555, (2-3), 2007, p194 - 198 Journal Article, 2007 DOI

R. McNamara, A. Kerans, B. O'Neill and A. Harkin, Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love") , Neuropharmacology, 50, (1), 2006, p69 - 80 Journal Article, 2006 DOI

T.J. Connor, C. Brewer, J.P. Kelly and A. Harkin, Acute stress suppresses pro-inflammatory cytokines TNF-alpha and IL-1beta independent of a catecholamine-driven increase in IL-10 production. , Journal of Neuroimmunology , 159, (1-2), 2005, p119 - 128 Journal Article, 2005 DOI

T.J. Connor, A. Harkin and J.P. Kelly , Methylenedioxymethamphetamine (MDMA; "Ecstasy") suppresses production of the pro-inflammatory cytokine tumor necrosis factor-alpha independent of a beta-adrenoceptor mediated increase in interleukin-10. , Journal of Pharmacology and Experimental Therapeutics , 312, (1), 2005, p134 - 143 Journal Article, 2005 DOI

Zueger M, Urani A, Chourbaji S, Zacher C, Roche M, Harkin A, Gass P., Olfactory bulbectomy in mice induces alterations in exploratory behavior, Neuroscience letters, 374, (2), 2005, p142 - 146 Journal Article, 2005 DOI

A. Harkin, T.J. Connor, M.P. Burns and J.P. Kelly, Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test., European Neuropsychopharmacology, 14, (4), 2004, p274 - 281 Journal Article, 2004 DOI

Connole L, Harkin A, Maginn M, Adenosine A(1) receptor blockade mimics caffeine's attenuation of ethanol-induced motor incoordination, Basic and Clinical Pharmacology and Toxicology, 95, (6), 2004, p299 - 304 Journal Article, 2004 DOI

A. Harkin, J.M. O'Donnell, J.P. Kelly, A combined and comparative study of physiologic and behavioural parameters in a systemic toxicity test, Contemporary Topics in Laboratory Animal Science , 42, (2), 2003, p30 - 37 Journal Article, 2003 URL

A. Harkin, E. Shanahan, J.P. Kelly and T.J. Connor , Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine., European Journal of Neuroscience, 18, (4), 2003, p1021 - 1027 Journal Article, 2003 DOI

A. Harkin, T.J. Connor, M. Walsh, St. John, N. and J.P. Kelly, Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors, Neuropharmacology, 44, (5), 2003, p616 - 623 Journal Article, 2003 DOI

A. Harkin, M.J. Hynes, E. Masterson, J.P. Kelly, J.M. O' Donnell and T.J. Connor, A toxicokinetic study of nickel-induced immunosuppression in rats. Immunopharmacol, Immunopharmacology and Immunotoxicology, 25, (4), 2003, p655 - 670 Journal Article, 2003 DOI

A. Harkin, J.P. Kelly, Leonard B.E. , A review of the relevance and validity of olfactory bulbectomy as a model of depression, Clinical Neurscience Research, 3, (4), 2003, p253 - 262 Journal Article, 2003 DOI

A. Harkin, T.J. Connor, J.M. O' Donnell and J.P. Kelly, Physiological and behavioral responses to stress: What does a rat find stressful ? , Lab Animal , 31, (4), 2002, p42 - 50 Journal Article, 2002

A. Harkin, J.M. O'Donnell, J.P. Kelly, A study of VitalView for behavioural and physiological monitoring in laboratory rats, Physiology & Behavior, 77, (1), 2002, p65 - 77 Journal Article, 2002 DOI

A. Harkin, D.D. Houlihan, J.P. Kelly, Reduction in preference for saccharin by repeated unpredictable stress in mice and its prevention by imipramine, Journal of Psychopharmacology, 16, (2), 2002, p115 - 123 Journal Article, 2002 URL

T.J. Connor, M.C. Dennedy, A. Harkin and J.P. Kelly, Methylenedioxymethamphetamine-induced suppression of interleukin-1β and tumour necrosis factor-α is not mediated by serotonin, European Journal of Pharmacology, 418, (1-2), 2001, p147 - 152 Journal Article, 2001 DOI

A. Harkin, T.J. Connor, J. Mulrooney, J.P. Kelly and B.E. Leonard, Prior exposure to methylenedioxyamphetamine (MDA) induces serotonergic loss and changes in spontaneous exploratory and amphetamine-induced behaviours in rats, Life Science, 68, (12), 2001, p1367 - 1382 Journal Article, 2001 DOI

A. Harkin, K. Morris, J.P. Kelly, J.M. O'Donnell, B.E. Leonard, Modulation of MK-801-induced behaviour by noradrenergic agents in mice, Psychopharmacology, 154, (2), 2001, p177 - 188 Journal Article, 2001 DOI

T.J. Connor, P. Kelliher, Y. Shen, A. Harkin, J.P. Kelly and B.E. Leonard, Effect of Subchronic Antidepressant Treatments on Behavioral, Neurochemical, and Endocrine Changes in the Forced-Swim Test, Pharmacology Biochemistry and Behavior, 65, (4), 2000, p591 - 597 Journal Article, 2000 DOI

A. Harkin, R. Nally, J.P. Kelly, B.E. Leonard , Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression, Journal of Neural Transmission, 107, (10), 2000, p1213 - 1227 Journal Article, 2000 DOI

A. Harkin, J.F. Cryan, M. Naughton, J.P. Kelly, B.E. Leonard , Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action, European Journal of Pharmacology, 390, (3), 2000, p275 - 285 Journal Article, 2000 DOI

A. Harkin, G. Nowak, I.A. Paul, Noradrenergic lesion antagonizes desipramine-induced adaptation of NMDA receptors, European Journal of Pharmacology, 389, (2-3), 2000, p187 - 192 Journal Article, 2000 DOI

P. Kelliher, T.J. Connor, A. Harkin, C. Sanchez, J.P. Kelly and B.E. Leonard, Varying responses to the rat forced swim test under diurnal and nocturnal conditions, Physiology & Behavior, 69, (4-5), 2000, p531 - 539 Journal Article, 2000 DOI

A. Harkin, J.P. Kelly, J. Frawley, J.M. O'Donnell, B.E. Leonard, Test conditions influence the response to a drug challenge in rodents., Pharmacology Biochemistry and Behavior, 65, (3), 2000, p389 - 398 Journal Article, 2000 DOI

T.J. Connor, A. Harkin, J.P. Kelly and B.E. Leonard, Olfactory bulbectomy provokes a suppression of interleukin-1beta and tumour necrosis factor-alpha production following an in vivo challenge with lipopolysaccharide: Effect of chronic desipramine treatment, Neuroimmunomodulation, 7, (1), 2000, p27 - 35 Journal Article, 2000 DOI

T.J. Connor, P. Kelliher, A. Harkin, J.P. Kelly and B.E. Leonard, Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat, European Journal of Pharmacology, 379, (2-3), 1999, p125 - 133 Journal Article, 1999 DOI

D.G. Healy, A. Harkin, J.F. Cryan, J.P. Kelly, B.E. Leonard, Metyrapone displays antidepressant-like properties in preclinical paradigms, Psychopharmacology, 145, (3), 1999, p303 - 308 Journal Article, 1999 DOI

A.M. Redmond, A. Harkin, J.P. Kelly, B.E. Leonard , Effects of acute and chronic antidepressant administration on phencyclidine induced locomotor hyperactivity, European Neuropsychopharmacology, 9, (1-2), 1999, p165 - 170 Journal Article, 1999 DOI

A. Harkin, J.P. Kelly, M. McNamara, T.J. Connor, K. Dredge, A. Redmond, B.E. Leonard, Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression, European Journal of Pharmacology, 364, (2-3), 1999, p123 - 132 Journal Article, 1999 DOI

A. Harkin, K.H. Bruce, B. Craft, I.A. Paul , Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test, European Journal of Pharmacology, 372, (2), 1999, p207 - 213 Journal Article, 1999 DOI

C.J. Faherty, A. Harkin, B.E. Leonard , The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment, European Journal of Pharmacology, 346, (1), 1998, p15 - 21 Journal Article, 1998 DOI

I. De Souza, J.P. Kelly, A. Harkin, B.E. Leonard , An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat, Pharmacology & Toxicology, 80, (5), 1997, p207 - 210 Journal Article, 1997 DOI

A. Harkin, J.P. Kelly, B.E. Leonard , Single or repeated administration of selective serotonin reuptake inhibitors fail to modulate apomorphine-induced responses in the rat., J. Serotonin Res, 3, 1996, p49 - 58 Journal Article, 1996

A. Harkin, J.P. Kelly, B.E. Leonard , The comparative effects of long-term administration of sertraline, paroxetine, citalopram, fluoxetine and amitryptyline on monoamine content in rat brain, J. Serotonin Res, 2, 1995, p181 - 190 Journal Article, 1995

Research Expertise

Description

My research falls within the remit of Neuropsychopharmacology, a discipline that links basic neuroscience to the pharmacological treatment of psychiatric and neurological disease. Selected examples of projects in these areas are outlined below: 1. Marie Curie Initial Training Networks (ITN): FP7-PEOPLE-2012-ITN Brain Imaging Return to Health "reBIRTH" see http://www.rbirth.eu/). The r'BIRTH consortium is a Marie Curie Initial Training Network that gathers experts on molecular mechanisms of age-associated pathologies including neurodegeneration and depression. They work together to identify stress-regulated molecules provoking neuronal atrophy and hindering neurogenesis (birth of new neurons), and monitor the consequences of these processes in human brain that contribute to cognitive decline and increased depressive and anxiety disorders associated with ageing. The work is funded by the European Commission (FP7) under the sub-programme PEOPLE (Marie Curie Actions). 16 early stage researchers will be trained in the topics of the programme i.e. molecular imaging (MRI), proteomics, immunotechnology, high content screening, molecular neuroscience, neuropharmacology and patient studies. The training is provided by seven universities, two private companies and one non-profit research organisation from 7 European countries. 2. Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system [Acronym: MOODINFLAME] Our research group is funded under EU FP7 as part of a collaborative, large-scale research project entitled "Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system. [Acronym: MOODINFLAME]. A consortium of 14 European Universities/Research Institutes and 4 SMEs have come together for this project with the overall objective of developing biomarker tests for mood disorder patients based on an activated inflammatory response system (IRS) and inflammation-mediated disturbances in tryptophan metabolism. As part of this programme patients are treated with drugs to counteract the consequences of an activated IRS/disturbed metabolism of tryptophan. The project leads to an enhanced understanding of the pathogenesis of inflammation-related mood disorders, and of the mechanism of anti-inflammatory drugs and drugs targeting tryptophan metabolism in treating depressive behaviour. 3. Neuronal nitric oxide synthase (nNOS): a novel target for antidepressant action. Inhibition of NMDA-R has shown considerable promise as a drug target to produce new antidepressants that work faster, and are more effective than existing antidepressants. We hypothesise that targeting signalling events down-stream of NMDA-R may provide a more viable approach. nNOS is a down stream target of NMDA-R. We have published a number of original papers demonstrating that 1) NOS inhibitors have antidepressant properties 2) such properties are dependent on endogenous serotonin and 3) NOS inhibitors can augment the effects of conventional antidepressants in preclinical models. Currently our research is assessing the efficacy of nNOS inhibitors as novel antidepressant agents. A future aim is to determine if uncoupling the NMDA-R from nNOS can elicit antidepressant actions. This work is funded by the Health research board.

Projects

  • Title
    • Brain Imaging Return to Health
  • Summary
    • Marie Curie Initial Training Networks (ITN): FP7-PEOPLE-2012-ITN Brain Imaging Return to Health "reBIRTH" (see http://www.rbirth.eu/) The r'BIRTH consortium is a Marie Curie Initial Training Network that gathers experts on molecular mechanisms of age-associated pathologies including neurodegeneration and depression. They work together to identify stress-regulated molecules provoking neuronal atrophy and hindering neurogenesis, and monitor the consequences of these processes in human brain. At the cellular level, diminished birth of new neurons (neurogenesis) contributes to cognitive decline and increased depressive and anxiety disorders that are associated with ageing. The work is funded by the European Commission (FP7) under the sub-programme PEOPLE (Marie Curie Actions). 16 early stage researchers will be trained in the topics of the programme i.e. molecular imaging (MRI), proteomics, immunotechnology, high content screening, molecular neuroscience, neuropharmacology and patient studies. The training is provided by seven universities, two private companies and one non-profit research organisation from 7 European countries.
  • Funding Agency
    • European Commission
  • Date From
    • 2014
  • Date To
    • 2018
  • Title
    • Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system.
  • Summary
    • [Acronym: MOODINFLAME] 2008-2013. A collaborative, large-scale focused research project entitled "Early diagnosis, treatment and prevention of mood disorders targeting the activated inflammatory response system. [Acronym: MOODINFLAME]. A consortium of 14 European Universities/Research Institutes and 4 SMEs have come together for this project with the overall objective of developing biomarker tests for mood disorder patients based on an activated inflammatory response system (IRS) and inflammation-mediated disturbances in tryptophan metabolism. As part of this programme patients are treated with drugs to counteract the consequences of an activated IRS/disturbed metabolism of tryptophan. The project leads to an enhanced understanding of the pathogenesis of inflammation-related mood disorders, and of the mechanism of anti-inflammatory drugs and drugs targeting tryptophan metabolism in treating depressive behaviour.
  • Funding Agency
    • EU 7th Framework
  • Date From
    • 2008
  • Date To
    • 2012
  • Title
    • Neuronal nitric oxide synthase: A novel target for antidepressant activity
  • Summary
    • Inhibition of N-methyl-D-aspartic acid receptors (NMDA-R) has shown considerable promise as a drug target to produce new antidepressants that work faster, and are more effective than existing antidepressants. However, targeting NMDA-R directly is problematic due to adverse effects. We hypothesise that targeting signalling events down-stream of NMDA-R may provide a more viable approach. nNOS is a down stream target of NMDA-R. We have published a number of original papers demonstrating that 1) NOS inhibitors have antidepressant properties 2) such properties are dependent on endogenous serotonin and 3) NOS inhibitors can augment the effects of conventional antidepressants in preclinical models. Currently our research is assessing the efficacy of nNOS inhibitors as novel antidepressant agents. A future aim is to determine if uncoupling the NMDA-R from nNOS can elicit antidepressant actions.
  • Funding Agency
    • Health Research Board
  • Date From
    • 2008
  • Date To
    • 2012
  • Title
    • Caffeine exacerbates the acute toxicity of 3,4 methylenedioxymethamphetamine (MDMA; "Ecstasy"): A role for dopamine ?
  • Summary
    • Co-administration of caffeine profoundly enhances the acute toxicity of MDMA. This project will elucidate the mechanism underlying a potentially serious drug interaction between caffeine and MDMA and clarify risks associated with the concurrent consumption of caffeine with other drugs which increase dopaminergic transmission.
  • Funding Agency
    • Health Research Board
  • Date From
    • 2006
  • Date To
    • 2009
  • Title
    • Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA
  • Summary
    • The project determined the effect of caffeine co-administration on the core body temperature response and long-term serotonin (5-HT) loss induced by methylenedioxymethamphetamine (MDMA; "Ecstasy") and its metabolite methylenedioxyamphetamine (MDA; "Love"). Caffeine promotes hyperthermia, tachycardia and long-term central serotonin loss associated with MDMA and MDA. This is a serious drug interaction, which could have important acute and long-term health consequences for recreational drug users.
  • Funding Agency
    • Irish Research Council for Science Engineering and Technology
  • Date From
    • 2003
  • Date To
    • 2006

Keywords

Addiction and substance abuse; Depression; Emotional, behavioural and cognitive disorders; Imaging Techniques; In vitro testing, trial methods; Neurobiology; Neurochemistry and neuropharmacology; Neuropharmacology; Neuroscience; Psychiatry

Recognition

Awards and Honours

Health Research Board career development fellowship 2002

CINP Young Investigator Award. 2004

Fellowship Trinity College Dublin 2011

Memberships

Psychoneuroimmunology Research Society 2010 – present

Collegium Internationale Neuro-Psychopharmacologicum 2003 – present

British Pharmacological Society 2003 – present

British Association for Psychopharmacology 1997 – present

Neuroscience Ireland 2012 – Present


Last updated 9 September 2016 by School of Pharmacy & Pharmaceutical Sciences (Email).